Oyster Point Pharma inks $93 mln Series B
Oyster Point Pharma Inc., a clinical-stage pharmaceutical company focused on treating dry eye disease, has secured $93 million in Series B financing. Invus Opportunities and Flying L Partners led the round.
26 February 2019•1 min read
